tbuckley/cabot-search huggingface dataset:
Abstract 14864: Impact of Chronic Atrial Fibrillation on 1-year Clinical Outcomes Following Percutaneous Transluminal Angioplasty in Patients With Symptomatic Peripheral Arterial Disease
Authors: Sang-Ho Park, Seung Woon Rha, Ung Jun, Byoung Geol Choi, Se Yeon Choi, Jae Kyeong Byun, Jin Oh Na, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh
Journal: Circulation (2015)

Background: To date, there is no study regarding the impact of chronic atrial fibrillation (AF) on clinical outcomes following percutaneous transluminal angioplasty (PTA) in patients (pts) with symptomatic peripheral arterial disease (PAD). Methods: We investigated the 512 consecutive symptomatic PAD pts underwent PTA from September 2004 to December 2013. Individual and composite cumulative clinical outcomes of PAD pts with AF (n=465) at 1 year were compared with those of PAD pts with normal sinus rhythm (NSR, n=47). Results: In baseline characteristics, there were no significant differences in baseline clinical characteristics including gender, smoking, hypertension, diabetes, dyslipidemia, cerebrovascular accident (CVA), chronic renal insufficiency, dialysis, coronary artery disease, myocardial infarction, symptoms of PAD such as claudication, resting pain, wound, and gangrene between the two groups except age; The AF group tended to be elder than non-AF group (67.15±10.56 years vs. 70.21±8.93 years, respectively, p=0.051). At 1 year, there was no significant differences in major clinical outcomes such as the incidence of repeat PTA, target lesion revascularization (TLR), target extremity revascularization (TER), target extremity surgery (TES), above-the-knee amputation, above-the-ankle amputation, below-the-ankle amputation, acute myocardial infarction (AMI), percutaneous coronary intervention (PCI), and major adverse cerebrocardiovascular events (MACCEs) between the two groups. However, after adjustment of baseline confounders, the incidence of total death, cardiac death, and CVA were higher in the AF group as compared with non-AF group (Table). Conclusions: In our study, symptomatic PAD pts underwent PTA combined with AF was associated with higher incidence of mortality and stroke up to 1-year as compared with PAD pts with NSR.
A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
Authors: Noah M. Hahn, Trinity J. Bivalacqua, Ashley E. Ross, George J. Netto, Alex Baras, Jong Chul Park, Carolyn Chapman, Timothy A. Masterson, Michael O. Koch, Richard Bihrle, Richard S. Foster, Thomas A. Gardner, Liang Cheng, David R. Jones, Kyle McElyea, George E. Sandusky, Timothy Breen, Ziyue Liu, Costantine Albany, Marietta L. Moore, Rhoda L. Loman, Angela Reed, Scott A. Turner, Francine B. De Abreu, Torrey Gallagher, Gregory J. Tsongalis, Elizabeth R. Plimack, Richard E. Greenberg, Daniel M. Geynisman
Journal: Clinical Cancer Research (2016)

Abstract Purpose: To assess the clinical and pharmacodynamic activity of dovitinib in a treatment-resistant, molecularly enriched non–muscle-invasive urothelial carcinoma of the bladder (NMIUC) population. Experimental Design: A multi-site pilot phase II trial was conducted. Key eligibility criteria included the following: Bacillus Calmette-Guerin (BCG)-unresponsive NMIUC (&amp;gt;2 prior intravesical regimens) with increased phosphorylated FGFR3 (pFGFR3) expression by centrally analyzed immunohistochemistry (IHC+) or FGFR3 mutations (Mut+) assessed in a CLIA-licensed laboratory. Patients received oral dovitinib 500 mg daily (5 days on/2 days off). The primary endpoint was 6-month TURBT-confirmed complete response (CR) rate. Results: Between 11/2013 and 10/2014, 13 patients enrolled (10 IHC+ Mut−, 3 IHC+ Mut+). Accrual ended prematurely due to cessation of dovitinib clinical development. Demographics included the following: median age 70 years; 85% male; carcinoma in situ (CIS; 3 patients), Ta/T1 (8 patients), and Ta/T1 + CIS (2 patients); median prior regimens 3. Toxicity was frequent with all patients experiencing at least one grade 3–4 event. Six-month CR rate was 8% (0% in IHC+ Mut−; 33% in IHC+ Mut+). The primary endpoint was not met. Pharmacodynamically active (94–5,812 nmol/L) dovitinib concentrations in urothelial tissue were observed in all evaluable patients. Reductions in pFGFR3 IHC staining were observed post-dovitinib treatment. Conclusions: Dovitinib consistently achieved biologically active concentrations within the urothelium and demonstrated pharmacodynamic pFGFR3 inhibition. These results support systemic administration as a viable approach to clinical trials in patients with NMIUC. Long-term dovitinib administration was not feasible due to frequent toxicity. Absent clinical activity suggests that patient selection by pFGFR3 IHC alone does not enrich for response to FGFR3 kinase inhibitors in urothelial carcinoma. Clin Cancer Res; 23(12); 3003–11. ©2016 AACR.
The treatment of hidradenitis suppurativa with the glucagon‐like peptide‐1 agonist liraglutide
Authors: L. Jennings, L. Nestor, O. Molloy, R. Hughes, B. Moriarty, B. Kirby
Journal: British Journal of Dermatology (2016)

Hidradenitis suppurativa (HS) is a cutaneous disease associated with systemic inflammation, obesity and metabolic syndrome. Effective treatment options are limited. The antidiabetic agents, incretins, have been used successfully to treat psoriasis - a disease also associated with metabolic syndrome. We report the use of liraglutide, a glucagon-like peptide-1 agonist, in a patient with HS, leading to subsequent weight loss and improvement in disease control. To our knowledge, this is the first report of liraglutide used in the treatment of HS.
Tumor Suppressor Activity of CCAAT/Enhancer Binding Protein Alpha Is Epigenetically Down-Regulated in Acute Myeloid Leukemia.
Authors: Tsung-Chin Lin, Cheng-Yeh Lee, Hwei-Fang Tien, Chung-Yi Hu, Jih-Luh Tang, Liang-In Lin
Journal: Blood (2007)
A Phase 3 Randomized, Historically-Controlled Clinical Trial Investigating the Use of Defibrotide in the Treatment of Severe Veno-Occlusive Disease Post-SCT: A Novel Approach to the Validation of a Promising New Drug for the Treatment of a Life Threatening Disease.
Authors: Paul Richardson, Nancy Kernan, Marcie Tomblyn, Paul Martin, Sally Arai, Joel Brochstein, Eva Guinan, Gideon Steinbach, Elizabeth Nemecek, Ralph D’Agostino, Carolyn Revta, Alison Hannah, Massimo Iacobelli, Robert Soiffer
Journal: Blood (2007)
Alejandra San Martin
Authors: Ruth Williams
Journal: Circulation Research (2016)

Her group studies vascular smooth muscle cell biology-in particular, how reactive oxygen species drive migration of these cells during normal physiology and cardiovascular disease. 1-5 San Martin likes to get her hands dirty at the bench, culturing cells and performing experiments, but there is more to this young investigator than meets the eye.On occasion, she's been known to put down her pipette and pick up a microphone.San Martin has always loved to sing.Indeed, it was a hobby she pursued with vehemence as a youngster.She's also a keen flamenco dancer.The coexistence of these artistic and academic sides to San Martin's character is not surprising given her upbringing in a family full of creative, cultural and intellectual influences.This childhood environment fostered an early love for learning, San Martin told Circulation Research.In fact, she was ultimately drawn to scientific research by the romance of the academic lifestyle, she says. Where Did You Grow Up?I grew up in Sant_iago Chile under the dictatorship of Augusto Pinochet.As a kid, it didn't appear that bad but, in retrospect, there were many things that I assumed were normal that really were not. Such As?Curfews at night, when nobody could be in the street, and the fact that we always had a supply of candles because power stations would regularly be attacked and destroyed by political protestors.These were part of everyday life.The country transitioned to a democracy in 1990, around the time I was going to college.It was liberating, especially because college is a time when you are very idealistic.
Pomalidomide Induces Expansion of Activated and Central Memory CD4+ and CD8+ T Cells in Vivo in Patients with and without HIV Infection
Authors: Mark N. Polizzotto, Irini Sereti, Thomas S. Uldrick, Kathleen M. Wyvill, Stig M. R. Jensen, Amrit Singh, Stephen B. Kovacs, Karen O. Aleman, Vickie Marshall, Denise Whitby, Frank Maldarelli, Seth M. Steinberg, Jerome B. Zeldis, Robert Yarchoan
Journal: Blood (2014)
Longitudinal Changes in Endocrine Disease in Thalassemia Major Patients on Different Iron Chelators
Authors: Maurizio Poggi, Francesco Sorrentino, Maria Rondinelli, Pellegrina Pugliese, maria Paola Smacchia, Carmine Daniele, Francesco Equitani, maria Rita Guitarrini, Lorenza Mattia, Maffei Laura, Losardo Anna, Filomena Terlizzi, Methap Pasin, Michela Capogna, Vincenzo Toscano
Journal: Blood (2015)
Cancer Care Institutions and Advertising—Reply
Authors: Lisa M. Schwartz, Steven Woloshin
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Perceived barriers and facilitators of mental health service utilization in adult trauma survivors: A systematic review
Authors: Viktoria Kantor, Matthias Knefel, Brigitte Lueger-Schuster
Journal: Clinical Psychology Review (2016)

Many trauma survivors seem to be reluctant to seek professional help. The aim of the current review was to synthesize relevant literature, and to systematically classify trauma survivors' perceived barriers and facilitators regarding mental health service utilization. The systematic search identified 19 studies addressing military personnel and 17 studies with trauma survivors of the general population. The data analysis revealed that the most prominent barriers included concerns related to stigma, shame and rejection, low mental health literacy, lack of knowledge and treatment-related doubts, fear of negative social consequences, limited resources, time, and expenses. Perceived facilitators lack attention in research, but can be influential in understanding mental health service use. Another prominent finding was that trauma survivors face specific trauma-related barriers to mental health service use, especially concerns about re-experiencing the traumatic events. Many trauma survivors avoid traumatic reminders and are therefore concerned about dealing with certain memories in treatment. These perceived barriers and facilitators were discussed regarding future research and practical implications in order to facilitate mental health service use among trauma survivors.
Castration resistance and high-risk disease among nonmetastatic (M0) prostate cancer (PC) patients on androgen deprivation therapy (ADT).
Authors: Melissa Pirolli, Rohini Khorana Hernandez, Karynsa Cetin, Jane Quigley, Yanina Grant-Huerta, Scott Stryker, Paul Smith, John Adams, Alexander Liede
Journal: Journal of Clinical Oncology (2012)

1581 Background: Prostate-specific antigen (PSA) is a well-known PC biomarker. In the M0 setting, rising PSAs despite ADT is an indication of the development of castration-resistant prostate cancer (CRPC). In this disease state, men are at risk for developing bone metastasis (BM), which is associated with significant morbidity and may negatively affect survival. Using real-world data, we explored PSA-based criteria to identify patients who develop CRPC while on ADT and the subsets that may be at increased risk of BM. Methods: We used the Oncology Services Comprehensive Electronic Records (OSCER) database, which includes electronic medical record (EMR) data on cancer patients from 328 urology and oncology clinics in the US. Eligible patients were adult men with M0 PC with ≥1 PSA recorded between 3/1/2010 and 2/28/2011 and currently receiving ADT (gonadotropin-releasing hormone agonists or bilateral orchiectomy) for ≥6 months (mos). We defined CRPC as two sequential PSA rises while on ADT and high risk for BM as any PSA ≥8 ng/mL or PSA doubling time (DT) ≤10 mos, as described by Smith MR et al, Lancet 2012. We explored subsets of CRPC patients who may be at even higher risk of BM using PSA thresholds (≥8 ng/mL and ≥20 ng/mL) and DT (≤4, 6, 8, and 10 mos). Results: Of 1,818 men with M0 PC receiving ADT ≥6 mos, 36% (N=646) met the CRPC definition, of whom 80% (N=517) had PSA ≥8 ng/mL and/or PSA DT ≤10 mos (high risk). PSA DT alone explained 63% (44% / 70%) to 93% (65% / 70%) of subgroup eligibility (Table), and emerged as a main driver in defining increased risk of BM for CRPC subsets. Conclusions: In this analysis of EMR data, over one-third of men with M0 PC on ADT met criteria for CRPC, and most CRPC patients (80%) may be considered at high risk for BM. Requiring ≥3 PSAs to define CRPC may be a limitation; however, because PSAs are closely monitored in patients on ADT, these definitions of CRPC and high risk may be useful in practice. These data suggest that PSA DT may be a more clinically meaningful measure of defining CRPC subsets than absolute PSA thresholds. [Table: see text] .
Intermethod comparison of breast receptor studies by immunohistochemistry and quantitative RT-PCR (21 gene assay).
Authors: R. S. Fulton, F. L. Baehner
Journal: Journal of Clinical Oncology (2011)

48 Background: The ASCO/CAP Guidelines mandate that laboratories performing HER2 and hormone receptor analyses monitor and correlate their results with results obtained from outside testing. Herein, we evaluate the concordance between results obtained by the 21 gene assay (ODx) with those performed by immunohistochemistry (IHC) at the Kaiser Permanente Northern California Regional IHC Laboratory (KP-NCAL). Methods: Sequential specimens from KP-NCAL were evaluated by IHC for ER (SP1), PR (PgR636) using 5% staining for positivity and HER2 (4B5) using &gt;30% with 3+ positivity. Standardized quantitative RT-PCR analysis for ER, PR and HER2 was performed using pre-defined cutoffs of 6.5, 5.5, 11.5 units. Reference normalized expression measurements ranged from 0 to 15, where each 1-unit increase reflects about a 2-fold increase in RNA. The percent positive agreement (PPA) and percent negative agreement (PNA) was calculated for each of the three markers. For the purposes of this inter-method comparison we define ODx as the reference test; in this comparison, a “true positive” is IHC+ and ODx+. A “false positive” would be IHC+ and ODx-. Results: Evaluable data was obtained from 216 sequential patients from 11/2009 to 5/2010 with both IHC (KP-NCAL) and the 21 gene assay (ODx) results. The HER2 PPA was 100%, PNA 99.4%. The ER PPA was 99.1%, PNA 100%. The PR PPA was 92%, PNA 52%. Conclusions: There is a high degree of agreement between KP-NCAL IHC and ODx results for ER and HER2. This level of agreement is particularly striking given that in &gt;90% of cases, IHC was performed on an initial biopsy, while the RT-PCR assay was performed on a subsequent excision specimen. The negative agreement for PR was moderate and suggests a possible lack of sensitivity in the IHC assay that needs to be studied further. [Table: see text]
Calcium metabolism in patients with castration-resistant prostate cancer: Development of a quantitative urinary assay for extent of bone metastasis.
Authors: Ashok P. Pai, Darren Hillegonds, Primo Lara, Chong-xian Pan, David Shelton
Journal: Journal of Clinical Oncology (2012)

130 Background: In patients with metastatic castration-resistant prostate cancer (CRPC), the degree of perturbation from normal bone turnover provides a strong indication of risk for disease progression, skeletal complications and death. Biomarkers of bone cell function and bone collagen degradation provide an integrated index of the underlying disease for patients with bony metastases, but available bone markers are not precise or accurate. In this study, patients with CRPC with bony metastases will consume a single oral calcium-41 dose and the pharmacokinetics of this will be measured over an 18 month period. Participants will also be assessed clinically for time to progression, skeletal related events and death. Methods: Patients with metastatic castration-resistant prostate cancer and bony metastatses, as diagnosed via bone scintigraphy, who were on bisphosphonates were enrolled into the study. 12 consenting research subjects consumed a single 1.2 microgram 41Ca tracer dose and provided 30-250mL urine specimens (single voids) after dose on day 1 (6h after dosing), days 7, 14, 28, 42, 60, and monthly thereafter. Isotope ratios were measured via accelerator mass spectrometry. Results: Urinary 41Ca/Ca was significantly and inversely associated with increased skeletal tumor burdens suggesting that development of an isotopic urine test for bone metastasis extent is feasible, providing a non-invasive and quantitative measure of disease extent. A calculation of the area under the curve of the measurements between day zero and 14 were inversely correlated with disease extent at baseline. Clinical deterioration with worsening bony disease was associated with a significant decrease in the urinary 41Ca/Ca value. We are currently assessing correlations between bone turnover and outcomes such as therapy effectiveness, disease progression, skeletal related events and death. Conclusions: This work is the first direct measurement of long-term calcium metabolism in advanced prostate cancer, providing a basic scientific complement to cellular and collagen-based measures of bone formation and resorption rates as well as a correlation to clinically relevant outcomes.
The association between metabolic syndrome and primary liver cancer: A meta-analysis.
Authors: Raxitkumar Jinjuvadia, Basile M. Njei, Ivo C. Ditah
Journal: Journal of Clinical Oncology (2012)

175 Background: The Metabolic syndrome (MetS) and/or its individual components have been liked to the development of cancer. Recent studies have suggested a similar link to Primary Liver Cancer (PLC). The mechanism for the development of cancer in this group of patients remains unclear. The aim of this study was to evaluate the direction and magnitude of the association between the MetS and PLC. Methods: Two reviewers independently conducted a systemic search of the PubMed, OvidSP and Cochrane Library databases from January 1980 to July 2011. Search terms included ‘Metabolic syndrome’, ‘insulin resistance syndrome’ combined with ‘hepatocellular carcinoma’, ‘liver cancer’ and ‘GI malignancy’. No language restriction was applied to the search. Only studies reporting an effect measure for the association between MetS and PLC were eligible for inclusion. Metabolic syndrome was defined according to NCEP/ATP III, IDF, AHA and WHO guidelines. Identified articles were reviewed for additional references. Combined analysis including all studies was done using a random effects model. Publication bias was assessed using the Begg and Egger’s tests, with a visual inspection of funnel plot. All analyses were performed using Comprehensive Meta-Analysis version 2 software. Results: Five studies (4 cohort and 1 case-control) including 863,714 participants were included in the analysis. The age range of participants was between 20 and 88 years. The combined analysis showed an overall 74% increase risk of PLC in cases with MetS (RR: 1.74, 95% CI: 1.36-2.24). After excluding the single case-control study from analysis, the overall risk ratio remained statistically significant (RR: 1.62, 95% CI: 1.22-2.15). Funnel plot inspection, Begg and Egger’s tests showed no evidence of publication bias, whether in the combined or subgroup analysis. Conclusions: Though studies are scarce, currently available epidemiologic data is suggestive of positive association with significantly higher risk of liver cancer among patients with metabolic syndrome. More studies are required before reaching conclusive statement regarding this association. Further better-designed studies with good quality data with definitely aid in strengthening this association.
Breast conservation therapy: The influence of molecules and margins.
Authors: S. Demirci, G. Broadwater, L. B. Marks, R. Clough, L. R. Prosnitz
Journal: Journal of Clinical Oncology (2011)

1065 Background: To evaluate treatment results and prognostic factors especially margin status and molecular subtype in early stage breast cancer patients treated with breast conservation therapy (BCT). Methods: The records of 1,058 stage I or II breast cancer patients treated with BCT (surgical excision plus radiotherapy) at Duke University Medical Center from 1985-2005 were retrospectively reviewed. Conventional receptor analyses were used as surrogate markers for molecular subtype classification (luminal A, luminal B, Her2 positive and basal like). Actuarial estimates of overall survival (OS), cause specific survival (CSS), failure free survival (FFS), and local-regional control (LRC) were computed using Kaplan-Meier plots. Prognostic variables were analyzed for significance utilizing Cox proportional hazards univariate and multivariate analysis. The study was approved by the Duke University Medical Center Institutional Review Board. Results: Median age of the patients was 56 (range:18-89). Eighty percent had T1 disease, 66% N0 disease pathologically. With a median followup of 9.8 years, 53 patients developed an in - breast recurrence and 10 had nodal failure. For all patients the 10 year CSS was 94%, LRC 94% and FFS 88%. Luminal A patients had a CSS of 95% and LRC of 99%. Basal type patients appeared to do worse, both with regard to CSS (74%) and LRC (76%), but the numbers are small and the difference not statistically significant. LRC rates of patients with negative margins (either widely negative or close, or with the extent of the margin not known) were virtually identical (93%, 96%, and 94% respectively). Those with positive margins appears to fair slightly worse LRC (88%), but again the numbers are small and the difference is not statistically significant. Conclusions: BCT remains the treatment of choice for early stage breast cancer patients irrespective of molecular subtype. Negative margins of excision are desirable but the width of the negative margin does not influence outcome
Bone Morphogenic Protein 6: A Prognostic Factor Expressed by Normal Plasma Cells and Multiple Myeloma Cells Inhibiting Their Proliferation and Angiogenesis Induction
Authors: Anja Seckinger, Tobias Meißner, Jérôme Moreaux, Hartmut Goldschmidt, Axel Benner, Michael Hundemer, Thierry Rème, John D. Shaughnessy, Bart Barlogie, Uta Bertsch, Jens Hillengass, Anthony D. Ho, Véronique Pantesco, Anna Jauch, John De Vos, Jean François Rossi, Thomas Möhler, Bernard Klein, Dirk Hose
Journal: Blood (2008)